规格 | 目录价格 | 上海 | 安徽 | 武汉 | 成都 | 北方 | 深圳 | 会员价格 | 数量 |
---|---|---|---|---|---|---|---|---|---|
5mg | ¥ ųǃǃƞǃǃ | > | -- | -- | -- | -- | -- | ¥ ųǃǃƞǃǃ | - + |
mg | ¥ ƖƖǃǃƞǃǃ | > | -- | -- | -- | -- | -- | ¥ ƖƖǃǃƞǃǃ | - + |
25mg | ¥ Ƿǃǃǃƞǃǃ | > | -- | -- | -- | -- | -- | ¥ Ƿǃǃǃƞǃǃ | - + |
50mg | ¥ üŒǃǃƞǃǃ | > | -- | -- | -- | -- | -- | ¥ üŒǃǃƞǃǃ | - + |
0mg | ¥ ŠǦǃǦƞǃǃ | > | -- | -- | -- | -- | -- | ¥ ŠǦǃǦƞǃǃ | - + |
250mg | ¥ ŒųŒǷƞǃǃ | > | -- | -- | -- | -- | -- | ¥ ŒųŒǷƞǃǃ | - + |
500mg | 请询价 | -- | -- | -- | -- | -- | -- | -- | - + |
1g | 请询价 | -- | -- | -- | -- | -- | -- | -- | - + |
5g | 请询价 | -- | -- | -- | -- | -- | -- | -- | - + |
19.22
[1]. Dabigatran
[2]. Preetpal Singh Sidhu,Aiye Liang, Akul Y. Mehta,et al. Rational Design of Potent, Small, Synthetic Allosteric Inhibitors of Thrombin. J Med Chem. 2011; 54(15): 5522-551.
[]. Santiago Redondo, Maria-Paz Martínez, Marta Ramajo, et al. Pharmacological basis and clinical evidence of dabigatran therapy. J Hematol Oncol. 2011; 4: 5.
[4]. Simon Michaelis, Anett Marais, Anna K. Schrey, et al. Dabigatran and Dabigatran Ethyl Ester: Potent Inhibitors of Ribosyldihydronicotinamide Dehydrogenase (NQO2). J. Med. Chem., 2012, 55 ():94-944
[5]. Stefan Blech, Thomas Ebner, Eva Ludwig-Schwellinger,et al. The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans. DMD ,200 , 6 (2) 6-99
H02-H15-H19-H5
P261-P264-P270-P271-P20-P02+P52-P04+P40-P05+P51+P-P0-P62+P64-P40+P2-P405-P501